Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-3: LY4268989 in Moderately to Severely Active Ulcerative Colitis
NCT07415044Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 2 trial of LY4268989 in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Started Mar 2026; status: recruiting.
02
Drugs
LY4268989
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07415044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07415044.